Complex Evolution of RA Management and Outcomes

Save

FIRST is a Japanese longitudinal, real world, registry of rheumatoid arthritis (RA) management and over the las 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain.

EULAR Guidelines on Reproductive Health

Save

FDA Approves Rinvoq for Giant Cell Arteritis

Save

Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib in the U.S. for use in rheumatology, gastroenterology, and dermatology.

Metformin Effective in Osteoarthritis

Save

The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said.

2024 Management of Familial Mediterranean Fever Recommendations

Save

A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs who care for FMF patients.

No Extra Cancer Recurrence Risk with Biologics in RA

Save

Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater likelihood of cancer relapse when they were treated with biologic agents, compared with conventional disease-modifying anti-rheumatic drugs (DMARDs).

Rheumatology: Believe It or Not (4/25/2025)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?

Vitamin D for Prevention of Disease

Save

JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults.

Unmet Needs in Still’s disease

Save

In February 2023, an expert consensus panel of pediatric and adult rheumatologists met to address challenges in Still’s disease (SD), including systemic juvenile idiopathic arthritis and adult-onset SD. They addressed four main topics: (1) early recognition and diagnosis of SD; (2) pathogenetic pathways and possible biomarkers for diagnosis and response; (3) refractory disease and risk factors, and (4) treatment of SD and its complications.

Better Responses with Chronotherapy for Baricitinib

Save

A nonrandomized, open-label, controlled trial has shown superior efficacy when baricitinib was given at night (instead of day); attesting to the benefits of chronotherapy - selective dosing meant to target the body's diurnal variations.

Post-treatment Lyme Syndrome

Save

Symptoms that persist long after Lyme disease is treated are not uncommon — a 2022 study found that 14% of patients who were diagnosed and treated early with antibiotic therapy would still develop Post Treatment Lyme Disease (PTLD). Yet doctors puzzle over the condition’s causes and how to help their patients through symptoms ranging from severe fatigue and cognitive challenges to body pain and arthritis.

2025 BSR Guideline for Treatment of Axial Spondyloarthritis

Save

The British Society of Rheumatology has published its 2025 Guidelines for the Treatment of Axial Spondyloarthritis (axSpA); addressing axial and extra-musculoskeletal manifestations including acute anterior uveitis, psoriasis and IBD.